Details for Patent: RE46363
✉ Email this page to a colleague
Which drugs does patent RE46363 protect, and when does it expire?
Patent RE46363 protects OZEMPIC and SAXENDA and is included in two NDAs.
Protection for SAXENDA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has nineteen patent family members in fifteen countries.
Summary for Patent: RE46363
Title: | Dial-down mechanism for wind-up pen |
Abstract: | The present invention relates to a dial-down mechanism for an injection device comprising a torsion spring for assisting injection of a dose of medicament from the injection device, the dial-down mechanism comprising dial-up cam arranged to receive and engage with a dial-up key, wherein the dial-up cam and the dial-up key are adapted to, upon rotation of a dose setting member in a first direction, cooperate to strain the torsion spring of the injection device, and a dial-down cam arranged to receive and engage with a dial-down key, wherein the dial-down cam and the dial-down key are adapted to, upon rotation of the dose setting member in a second direction, cooperate to release the torsion spring of the injection device, the second rotation direction being opposite to the first rotation direction. |
Inventor(s): | Moeller; Claus Schmidt (Fredensborg, DK), Enggaard; Christian Peter (Vejby, DK), Radmer; Bo (Hilleroed, DK), Markussen; Tom Hede (Bagsvaerd, DK) |
Assignee: | Novo Nordisk A/S (Bagsvaerd, DK) |
Application Number: | 14/091,774 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent RE46363 |
Patent Claim Types: see list of patent claims | Use; Delivery; Device; |
Drugs Protected by US Patent RE46363
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-001 | Dec 5, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-004 | Oct 6, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-002 | Apr 9, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: RE46363
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
04077900 | Oct 21, 2004 |
PCT Information | |||
PCT Filed | October 20, 2005 | PCT Application Number: | PCT/EP2005/011285 |
PCT Publication Date: | May 04, 2006 | PCT Publication Number: | WO2006/045526 |
International Family Members for US Patent RE46363
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | E444090 | ⤷ Try a Trial | |||
Australia | 2005298944 | ⤷ Try a Trial | |||
Canada | 2584760 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |